<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437943</url>
  </required_header>
  <id_info>
    <org_study_id>2010P000005</org_study_id>
    <nct_id>NCT01437943</nct_id>
  </id_info>
  <brief_title>Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients</brief_title>
  <official_title>P-MR Spectroscopy Evaluation of the Effect of Short-Term Treatment With Aliskiren on Kidney β-ATP/Pi Level in Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of a short-term aliskiren treatment on
      kidney metabolism in patients at high risk for developing kidney dysfunction (i.e. kidney
      transplanted patients). The study is aimed at evaluating if any effect on kidney metabolism
      [using proton MR Spectroscopy(1H-MRS)] can be detected following a 6 months treatment with
      aliskiren regardless of its anti-hypertensive role. 1H-MRS can record a larger number of
      chemical species (up to 40) in the kidney, and monitor changes according to the pathologic
      state and health of the transplanted kidney.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Novartis has have decided to terminate all clinical investigator-initiated research projects
    involving aliskiren
  </why_stopped>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Aliskiren on Kidney Metabolism</measure>
    <time_frame>180 days (completion of treatment)</time_frame>
    <description>Evaluation of aliskiren on kidney metabolism by P-MR spectroscopy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Kidney Disease</condition>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aliskiren 150 mg daily for 180 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo identical to Aliskiren drug daily for 180 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>Take 1 tablet (150 mg) by mouth daily for 180 days</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Tekturna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Take 1 tablet (0 mg) daily for 180 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable patients with end stage renal disease receiving cadaveric kidney
             transplantation will be enrolled. Patients must have at least 6 months of follow-up to
             be included in the study. Patients must have stable creatinine levels in the last 6
             months (no change&gt;0.5 mg/dl).

          -  Patients with a systolic blood pressure of 120 or above

        Exclusion Criteria:

          -  Serum potassium &gt; 5.0 mmol/L (at the visit directly preceding Randomization);

          -  History of any cardiovascular event (stroke, TIA, MI, unstable angina, CABG,
             percutaneous coronary intervention, hospitalization due to HF) during the 3 months
             prior to Visit 1. If a patient experiences such an event between Visit 1 and
             randomization at Visit 3, he/she should be withdrawn from the screening phase. If
             suitable, the patient can be re-screened at a later stage;

          -  Hypertension (at enrollment): any patient with msSBP ≥ 170 mmHg or msDBP ≥ 110 mmHg;

          -  Congestive heart failure NYHA class III and IV;

          -  Concomitant treatment with two (2) or more renin-angiotensin-aldosterone system
             blocking agents, e.g. ACEI, ARB or aldosterone-antagonist;

          -  Unstable serum creatinine, no patients with creatinine &gt;2.5 mg/dl will be enrolled;

          -  Second (II) or third (III) degree heart block without a pacemaker;

          -  Concurrent potentially life threatening arrhythmia or other uncontrolled arrhythmia;

          -  Clinically significant valvular heart disease;

          -  Known renal artery stenosis;

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of the study drugs including, but not limited
             to, any of the following: (i) History of major gastrointestinal tract surgery such as
             gastrectomy, gastroenterostomy, or bowel resection (patients with previous bariatric
             surgery &gt; 6 months prior to Visit 1 are allowed to participate); (ii) Any history of
             pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as
             indicated by abnormal lipase or amylase; (iii) Evidence of hepatic disease as
             determined by any one of the following: SGPT value exceeding 3 x Upper Limit of Normal
             (ULN) at Visit 1, a history of hepatic encephalopathy, a history of cirrhosis,
             esophageal varices, or a history of portocaval shunt.

          -  History of malignancy other than basal cell skin cancer within the past five years.

          -  Any concurrent life threatening condition with a life expectancy less than 2 years.

          -  History or evidence of drug or alcohol abuse within the last 12 months.

          -  Any surgical or medical condition, which in the opinion of the investigator, may place
             the patient at higher risk from his/her participation in the study, or is likely to
             prevent the patient from complying with the requirements of the study or completing
             the study.

          -  History of hypersensitivity to any of the study drugs or to medications belonging to
             the same therapeutic class as the study drugs as well as known or suspected
             contraindications to the study drugs.

          -  History of noncompliance to medical regimens or unwillingness to comply with the study
             protocol.

          -  Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer

          -  Any condition that in the opinion of the investigator would jeopardize the evaluation
             of efficacy or safety.

          -  Persons directly involved in the execution of this protocol.

          -  Pregnant or nursing (lactating) women

          -  Women of Child-Bearing Potential (WOCBP) unless postmenopausal for at least one year,
             surgically sterile or using effective methods of contraception as defined by local
             Health Authorities.

          -  Treatment with Cyclosporine.

        Exclusion criteria include MR contraindications:

          -  electrical implants such as cardiac pacemakers or perfusion pumps

          -  ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial
             hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or
             steel implants

          -  ferromagnetic objects such as jewelry or metal clips in clothing

          -  pregnant volunteers

          -  pre-existing medical conditions including a likelihood of developing seizures or
             claustrophobic reactions

          -  any greater than normal potential for cardiac arrest

          -  subjects less than 18 years of age.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anil Chandraker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <results_first_submitted>January 15, 2017</results_first_submitted>
  <results_first_submitted_qc>March 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 1, 2017</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Anil K. Chandraker, MD</investigator_full_name>
    <investigator_title>Medical Director of Renal Transplantation</investigator_title>
  </responsible_party>
  <keyword>Transplant</keyword>
  <keyword>Failure</keyword>
  <keyword>Kidney</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>10 subjects were recruited into the trial however none completed the treatment/follow-up as Novartis terminated all studies involving Aliskiren.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>Aliskiren 150 mg daily for 180 days
Aliskiren: Take 1 tablet (150 mg) by mouth daily for 180 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo daily for 180 days
Placebo: Take 1 tablet by mouth daily for 180 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Aliskiren trials terminated by Novartis</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject expressed pregnancy plans</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren</title>
          <description>Aliskiren 150 mg daily for 180 days
Aliskiren: Take 1 tablet (150 mg) by mouth daily for 180 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo daily for 180 days
Placebo: Take 1 tablet (0 mg) daily for 180 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.6" lower_limit="42" upper_limit="75"/>
                    <measurement group_id="B2" value="48" lower_limit="33" upper_limit="64"/>
                    <measurement group_id="B3" value="54" lower_limit="33" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Effect of Aliskiren on Kidney Metabolism</title>
        <description>Evaluation of aliskiren on kidney metabolism by P-MR spectroscopy</description>
        <time_frame>180 days (completion of treatment)</time_frame>
        <population>Only one subject completed study drug and no subjects had completed the 6 month P-MR scan at the time the trial was terminated. Because of this, we were not able to analyze the primary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>Aliskiren 150 mg daily for 180 days
Aliskiren: Take 1 tablet (150 mg) by mouth daily for 180 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo identical to Aliskiren drug daily for 180 days
Placebo: Take 1 tablet (0 mg) daily for 180 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Aliskiren on Kidney Metabolism</title>
          <description>Evaluation of aliskiren on kidney metabolism by P-MR spectroscopy</description>
          <population>Only one subject completed study drug and no subjects had completed the 6 month P-MR scan at the time the trial was terminated. Because of this, we were not able to analyze the primary outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected continuously during subject participation starting at consent through month 6 or termination of the trial.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren</title>
          <description>Aliskiren 150 mg daily for 180 days
Aliskiren: Take 1 tablet (150 mg) by mouth daily for 180 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo daily for 180 days
Placebo: Take 1 tablet by mouth daily for 180 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Left knee hemarthrosis and DVT</sub_title>
                <description>s/p left knee arthroscopy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleed</sub_title>
                <description>possible diverticulitis</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Salmonella group B</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lower extremity weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>In December 2011, all studies involving Aliskiren were terminated by Novartis after interim analysis of the ALTITUDE trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Anil Chandraker, MD</name_or_title>
      <organization>Brigham and Women's Hospital</organization>
      <phone>617-732-7412</phone>
      <email>achandraker@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

